Summary
The Overarching Objective for this consortium is to establish an inter-agency and multidisciplinary staff exchange programme between researchers, technical and administrative staff interaction within EU institutions as well as reaching out to non-EU countries in Africa, Lebanon and US in order to foster sharing of best practice in Newborn Screening, diagnosis and treatment of Sickle Cell Disease (SCD) leading to improvement in overall disease outcome. Using implementation science strategies for this consortium to foster partnerships and the establishment of patient database, registries and a sustainable service for people living with the disorder.
Primary Objectives:
- To evaluate the prevalence of sickle cell disease among populations in consortium member countries and identify specific haemoglobin genotypes and phenotypic presentations;
- To establish laboratory diagnosis and quality assurance systems for population screening and setting up of SCD national prevention programmes;
- To test the feasibility for establishing newborn and early infant screening for SCD in consortium participants;
- To establish treatment protocols for common complications -acute and chronic pain, stroke, infections, severe anaemia as well as transition from paediatric to adult care, health promotion strategies and nutrition.
In order to achieve these objectives, we designed the following WPs:
Scientific Coordination and Project Management
Implementing eHealth technologies to support a Newborn screening programme in EU, African Countries and Lebanon.
Improving laboratory diagnosis and quality assurance systems for population screening.
Newborn SCD screening, screening for neurocognitive complications, clinical care and antibiotic prophylaxis
Enhancement of SCD management through training in molecular diagnostic techniques and Genetic Counseling for haemoglobinopathies and performance of epidemiological and
Training in Research and academic leadership.
Communication and dissemination
Primary Objectives:
- To evaluate the prevalence of sickle cell disease among populations in consortium member countries and identify specific haemoglobin genotypes and phenotypic presentations;
- To establish laboratory diagnosis and quality assurance systems for population screening and setting up of SCD national prevention programmes;
- To test the feasibility for establishing newborn and early infant screening for SCD in consortium participants;
- To establish treatment protocols for common complications -acute and chronic pain, stroke, infections, severe anaemia as well as transition from paediatric to adult care, health promotion strategies and nutrition.
In order to achieve these objectives, we designed the following WPs:
Scientific Coordination and Project Management
Implementing eHealth technologies to support a Newborn screening programme in EU, African Countries and Lebanon.
Improving laboratory diagnosis and quality assurance systems for population screening.
Newborn SCD screening, screening for neurocognitive complications, clinical care and antibiotic prophylaxis
Enhancement of SCD management through training in molecular diagnostic techniques and Genetic Counseling for haemoglobinopathies and performance of epidemiological and
Training in Research and academic leadership.
Communication and dissemination
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/824021 |
Start date: | 01-01-2019 |
End date: | 31-10-2024 |
Total budget - Public funding: | 2 106 800,00 Euro - 2 106 800,00 Euro |
Cordis data
Original description
The Overarching Objective for this consortium is to establish an inter-agency and multidisciplinary staff exchange programme between researchers, technical and administrative staff interaction within EU institutions as well as reaching out to non-EU countries in Africa, Lebanon and US in order to foster sharing of best practice in Newborn Screening, diagnosis and treatment of Sickle Cell Disease (SCD) leading to improvement in overall disease outcome. Using implementation science strategies for this consortium to foster partnerships and the establishment of patient database, registries and a sustainable service for people living with the disorder.Primary Objectives:
- To evaluate the prevalence of sickle cell disease among populations in consortium member countries and identify specific haemoglobin genotypes and phenotypic presentations;
- To establish laboratory diagnosis and quality assurance systems for population screening and setting up of SCD national prevention programmes;
- To test the feasibility for establishing newborn and early infant screening for SCD in consortium participants;
- To establish treatment protocols for common complications -acute and chronic pain, stroke, infections, severe anaemia as well as transition from paediatric to adult care, health promotion strategies and nutrition.
In order to achieve these objectives, we designed the following WPs:
Scientific Coordination and Project Management
Implementing eHealth technologies to support a Newborn screening programme in EU, African Countries and Lebanon.
Improving laboratory diagnosis and quality assurance systems for population screening.
Newborn SCD screening, screening for neurocognitive complications, clinical care and antibiotic prophylaxis
Enhancement of SCD management through training in molecular diagnostic techniques and Genetic Counseling for haemoglobinopathies and performance of epidemiological and
Training in Research and academic leadership.
Communication and dissemination
Status
SIGNEDCall topic
MSCA-RISE-2018Update Date
28-04-2024
Images
No images available.
Geographical location(s)